All In Biotech

Drug Trial Radar · NCT06079879

A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006)

A Phase 3, Randomized, Open-label, Active-Comparator-Controlled Clinical Study to Evaluate the Safety and Efficacy of Bomedemstat (MK-3543/IMG-7289) Versus Best Available Therapy (BAT) in Participants With Essential Thrombocythemia Who Have an Inadequate Response to or Are Intolerant of Hydroxyurea

Last checked: Nov 19, 2026Latest source record: Oct 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 340 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

340

Planned (sponsor's estimate)

Start

Dec 31, 2023

Primary completion

Jul 14, 2027

Study completion Aug 18, 2028

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
Oct 12, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a study evaluating the safety and efficacy of bomedemstat (MK-3543) compared with the best available therapy (BAT) in participants with essential thrombocythemia (ET) who have an inadequate response to or are intolerant of hydroxyurea. The primary study hypothesis is that bomedemstat is superior to the best available therapy with respect to durable clinicohematologic response (DCHR).

Conditions

  • Essential Thrombocythemia

Interventions

  • BomedemstatDrug

    Oral Capsule

  • AnagrelideDrug

    Oral Capsule

  • BusulfanDrug

    Oral Tablet

  • Interferon alfa/pegylated interferon alfa 2a/pegylated interferon alfa 2bDrug

    Subcutaneous Solution

  • RuxolitinibDrug

    Oral Tablet

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Durable Clinicohematologic Response (DCHR) RateTime frame: Up to approximately 52 weeks

Locations

161 sites in 24 countries. Site status is shown where the registry gives one.

  • Palo Verde Hematology/ Oncology Center, Ltd. ( Site 3496)

    Glendale, Arizona

  • Los Angeles Cancer Network ( Site 3491)

    Glendale, California

  • Stanford Cancer Institute ( Site 0107)

    Stanford, California

  • The Lundquist Institute ( Site 3423)

    Torrance, California

  • University of Colorado Anschutz Medical Campus ( Site 3425)

    Aurora, Colorado

  • Tufts Medical Center ( Site 3408)

    Boston, Massachusetts

  • University of Michigan ( Site 0008)

    Ann Arbor, Michigan

  • Henry Ford Hospital ( Site 3413)

    Detroit, Michigan

  • Optum Care Cancer Center ( Site 3497)

    Las Vegas, Nevada

  • Roswell Park Cancer Institute ( Site 3421)

    Buffalo, New York

  • Duke University Health System (DUHS) ( Site 0016)

    Durham, North Carolina

  • Wake Forest Baptist Health-Internal Medicine, Section on Hematology & Oncology ( Site 3400)

    Winston-Salem, North Carolina

  • Medical University of South Carolina-Hollings Cancer Center ( Site 3426)

    Charleston, South Carolina

  • University of Virginia ( Site 3422)

    Charlottesville, Virginia

  • VCU Health Adult Outpatient Pavillion ( Site 3416)

    Richmond, Virginia

  • Hospital Universitario Austral ( Site 0104)

    Pilar, Buenos Aires, Argentina

  • Hospital Italiano de Buenos Aires ( Site 0105)

    ABB, Buenos Aires F.D., Argentina

  • C.I.C.E. 9 de Julio ( Site 1001)

    San Miguel de Tucumán, Tucumán Province, Argentina

  • Royal Prince Alfred Hospital ( Site 1100)

    Camperdown, New South Wales, Australia

  • Liverpool Hospital-Haematology ( Site 0501)

    Liverpool, New South Wales, Australia

  • Royal North Shore Hospital ( Site 0003)

    St Leonards, New South Wales, Australia

  • Calvary Mater Newcastle ( Site 0505)

    Waratah, New South Wales, Australia

  • Royal Adelaide Hospital-Haematology Clinical Trials Unit ( Site 0001)

    Adelaide, South Australia, Australia

  • Monash Health-Haematology Research ( Site 0006)

    Clayton, Victoria, Australia

  • Western Health-Sunshine & Footscray Hospitals-Cancer Services-Cancer Research ( Site 0502)

    Melbourne, Victoria, Australia

  • Royal Perth Hospital-Haematology ( Site 0504)

    Perth, Western Australia, Australia

  • ZAS Cadix ( Site 1200)

    Antwerp, Belgium

  • The Moncton Hospital-Oncology ( Site 1500)

    Moncton, New Brunswick, Canada

  • The First Afflilated Hospital of Bengbu Medical College ( Site 3509)

    Bengbu, Anhui, China

  • Anhui Provincial Hospital ( Site 3513)

    Hefei, Anhui, China

  • Peking University Third Hospital-Hematology ( Site 3502)

    Beijing, Beijing Municipality, China

  • Peking Union Medical College Hospital ( Site 3531)

    Beijing, Beijing Municipality, China

  • The Second Affiliated Hospital Of Fujian Medical University ( Site 3525)

    Quanzhou, Fujian, China

  • The First Affiliated hospital of Xiamen University ( Site 3515)

    Xiamen, Fujian, China

  • Sun Yat-sen Memorial Hospital of Sun Yat-sen University ( Site 3524)

    Guangzhou, Guangdong, China

  • Southern Medical University Nanfang Hospital-Department of Hematopathology ( Site 3511)

    Guangzhou, Guangdong, China

  • The First Hospital of Hebei Medical University ( Site 3510)

    Shijiazhuang, Hebei, China

  • Henan Cancer Hospital-hematology department ( Site 3504)

    Zhengzhou, Henan, China

  • Wuhan Union Hospital ( Site 3500)

    Wuhan, Hubei, China

  • Jiangsu Province Hospital ( Site 3507)

    Nanjing, Jiangsu, China

Showing 40 of 161 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.